EE200300169A - Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks - Google Patents

Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks

Info

Publication number
EE200300169A
EE200300169A EEP200300169A EEP200300169A EE200300169A EE 200300169 A EE200300169 A EE 200300169A EE P200300169 A EEP200300169 A EE P200300169A EE P200300169 A EEP200300169 A EE P200300169A EE 200300169 A EE200300169 A EE 200300169A
Authority
EE
Estonia
Prior art keywords
cyclooxygenase
inhibitors
prevention
cardiovascular disease
cardiovascular
Prior art date
Application number
EEP200300169A
Other languages
English (en)
Estonian (et)
Inventor
Roniker Barbara
J. Lachapelle Richard
T. Connolly Daniel
Seibert Karen
Needleman Philip
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Publication of EE200300169A publication Critical patent/EE200300169A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200300169A 1997-04-18 1998-04-16 Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks EE200300169A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4462697P 1997-04-18 1997-04-18
PCT/US1998/007318 WO1998047509A1 (en) 1997-04-18 1998-04-16 Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders

Publications (1)

Publication Number Publication Date
EE200300169A true EE200300169A (et) 2003-06-16

Family

ID=21933403

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200300169A EE200300169A (et) 1997-04-18 1998-04-16 Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
EEP199900517A EE9900517A (et) 1997-04-18 1998-04-16 Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP199900517A EE9900517A (et) 1997-04-18 1998-04-16 Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks

Country Status (26)

Country Link
EP (2) EP0979077A1 (id)
JP (1) JP2001527542A (id)
KR (1) KR20010006443A (id)
CN (1) CN1253502A (id)
AP (1) AP9901674A0 (id)
AU (1) AU745797B2 (id)
BG (1) BG103803A (id)
BR (1) BR9808932A (id)
CA (1) CA2286673A1 (id)
EA (1) EA199900837A1 (id)
EE (2) EE200300169A (id)
GE (1) GEP20022812B (id)
HU (1) HUP0001777A3 (id)
ID (1) ID23687A (id)
IL (1) IL132163A0 (id)
IS (1) IS5203A (id)
NO (1) NO995077L (id)
NZ (1) NZ500141A (id)
OA (1) OA11261A (id)
PL (1) PL337098A1 (id)
SK (1) SK138799A3 (id)
TR (1) TR199902545T2 (id)
UA (1) UA68348C2 (id)
WO (1) WO1998047509A1 (id)
YU (1) YU53899A (id)
ZA (1) ZA983249B (id)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US7030152B1 (en) * 1997-04-02 2006-04-18 The Brigham And Women's Hospital, Inc. Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
AU782386C (en) * 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1520590A1 (en) * 1999-08-31 2005-04-06 The Brigham and Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1767222A1 (en) * 1999-08-31 2007-03-28 The Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
UA76475C2 (en) * 2001-07-19 2006-08-15 Pharmacia Corp Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system
EP1434782A2 (en) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
KR100686537B1 (ko) * 2001-12-28 2007-02-27 씨제이 주식회사 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체
AU2003217276A1 (en) * 2002-02-28 2003-09-16 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
HRP20050168A2 (en) 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection
EP1400243A1 (en) * 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
JP2004189711A (ja) * 2002-12-11 2004-07-08 Raul Altman 急性冠動脈症候群および関連病態の治療のための抗血小板薬と組合せたメロキシカムの使用
US7572922B2 (en) 2003-01-27 2009-08-11 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2606106A1 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
CA2853804C (en) 2011-10-28 2021-06-01 Vitalis Llc Anti-flush compositions
CN115671097B (zh) * 2022-08-23 2024-02-13 上海交通大学医学院附属第九人民医院 用于防治动脉粥样硬化及斑块不稳定性的化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3103372A1 (de) * 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue indanyl-derivate, ihre herstellung und verwendung
JP2893903B2 (ja) * 1990-09-12 1999-05-24 藤沢薬品工業株式会社 虚血―再灌流障害予防、治療剤
JP3086312B2 (ja) * 1991-10-28 2000-09-11 富山化学工業株式会社 インターロイキン６の産生抑制剤並びにその産生抑制作用が有効な疾患の治療・予防剤
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
ES2141916T3 (es) * 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
EP0772606A1 (en) * 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
ES2183935T3 (es) * 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
CA2221692A1 (en) * 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DE69635048T2 (de) * 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
CA2286673A1 (en) 1998-10-29
SK138799A3 (en) 2001-01-18
UA68348C2 (en) 2004-08-16
JP2001527542A (ja) 2001-12-25
EP0979077A1 (en) 2000-02-16
YU53899A (sh) 2002-10-18
AP9901674A0 (en) 1999-12-31
AU745797B2 (en) 2002-03-28
PL337098A1 (en) 2000-07-31
BG103803A (bg) 2000-05-31
GEP20022812B (en) 2002-10-25
IL132163A0 (en) 2001-03-19
KR20010006443A (ko) 2001-01-26
TR199902545T2 (xx) 2000-01-21
CN1253502A (zh) 2000-05-17
BR9808932A (pt) 2000-08-01
NZ500141A (en) 2002-05-31
WO1998047509A1 (en) 1998-10-29
EA199900837A1 (ru) 2000-10-30
HUP0001777A2 (hu) 2001-05-28
EE9900517A (et) 2000-06-15
HUP0001777A3 (en) 2001-07-30
NO995077D0 (no) 1999-10-18
AU7466298A (en) 1998-11-13
EP1498140A2 (en) 2005-01-19
NO995077L (no) 1999-12-17
ZA983249B (en) 1999-04-19
IS5203A (is) 1999-09-30
OA11261A (en) 2003-07-24
ID23687A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
EE200300169A (et) Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
ID19198A (id) Inhibitor metaloprotease heterosiklik
ID18416A (id) Inhibitor metaloprotease diheterosiklik
ID23983A (id) Inhibitor-inhibitor aminotiazol untuk kinase-kinase tergantung siklin
EP0777478A4 (en) INHIBITORS OF ROTAMASE ENZYMATIC ACTIVITY
NO20000464L (no) Acykliske metalloprotease-inhibitorer
IS4771A (is) Interlevkín-1ß umbreytiensím tálmar
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
FI20012510L (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
PT944631E (pt) Novos derivados substituidos de pirazole para tratamento de doencas cardiovasculares
NO981708L (no) FremgangsmÕte for deteksjon av cyklooksygenase-2
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
PT958287E (pt) Inibidores de sulfamida-metaloprotease
PT927183E (pt) Inibidores espirociclicos de metaloproteases
NO983957D0 (no) Fremgangsmåte ved sammenföyning av tofase rustfritt stål
NO996090L (no) Forbedret foskefor og fremgangsmåte for anvendelse av dette
IL129604A0 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NO20021937D0 (no) Fremgangsmåte for administrering av en fosfodiesterase 4- hemmer
NO20000706L (no) Metode for økning av biotilgjengeligheten av fexofenadin og dens derivater
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
ID28227A (id) Penggunaan farmasi baru untuk inhibitor nos
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
EE04059B1 (et) Kloropuriinvaheühendite sünteesimeetod
ID19540A (id) Metode pembuatan turunan-turunan benzofenon
BR9610514A (pt) Inibidores cicloantihelmínticos